Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates

Haematologica

Volumn 100, Issue 7, 2015, Pages e261-e264

  Boer, Judith M ^a   Koenders, Jasper E ^b   Van Der Holt, Bronno ^c   Exalto, Carla ^b   Sanders, Mathijs A ^b   Cornelissen, Jan J ^b   Valk, Peter J M ^b   Den Boer, Monique L ^a   Rijneveld, Anita W ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

B cell precursor acute lymphoblastic leukemia; BCR ABL like acute lymphoblastic leukemia; Expression profiling; Outcome

Indexed keywords

DASATINIB; DNA BINDING PROTEIN; DNA BINDING PROTEIN IKAROS; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; IKAROS TRANSCRIPTION FACTOR; IKZF1 PROTEIN, HUMAN; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; LETTER; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; ONCOGENE; OUTCOME ASSESSMENT; PROGNOSTIC ASSESSMENT; ALLOTRANSPLANTATION; CLINICAL TRIAL; GENE EXPRESSION PROFILING; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; REMISSION; SURVIVAL ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; IKAROS TRANSCRIPTION FACTOR; IMATINIB MESYLATE; MIDDLE AGED; MUTATION; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84936119168     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.117424     Document Type: Letter

References (17)

1. Cornelissen JJ, van der Holt B, Verhoef GE, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood. 2009;113(6):1375-1382.
2. Rijneveld AW, van der Holt B, Daenen SM, et al. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia. 2011;25(11):1697-1703.
3. de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18(12):2032-2035.
4. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(02):125-134.
5. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480.
6. Tokunaga K, Yamaguchi S, Iwanaga E, et al. High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia. Eur J Haematol. 2013;91(3):201-208.
7. Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009;114(10):2159-2167.
8. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008; 453(7191):110-114.
9. Van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122(15):2622-2629.
10. Daenen S, van der Holt B, Dekker AW, et al. Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON. Leukemia. 2012;26(7):1726-1729.
11. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015.
12. Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 2010;24(7):1258-1264.
13. Dorge P, Meissner B, Zimmermann M, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2013;98(3):428-432.
14. Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27(31):5202-5207.
15. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):153-166.
16. Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1- PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013; 31(25):e413-416.
17. Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDFRB fusion. Haematologica. 2013;98(11):e146-148.